Panbela Therapeutics Inc.
PBLA
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.89K
Close$
Share Statistics
| Market cap | $53,889.00 |
|---|---|
| Enterprise Value | $3.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-232429.55 |
| Beta | 1.88 |
| Outstanding Shares | 4,854,861 |
Return
| Return on Equity | 153.59% |
|---|---|
| Return on Assets | -539.96% |
| Return on Invested Capital | 295.89% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0.02 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 29, 2026
EPS Estimate
$-2640.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-5160.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Panbela Therapeutics Inc
6 employees
CEO: Michael Cullen Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients ...